NCT06681506 A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease
| NCT ID | NCT06681506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 10th People's Hospital |
| Condition | Ischemic Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiac rehabilitation is an important link in cardiovascular disease. This study mainly explores the effectiveness of new cardiac rehabilitation therapy (early respiratory rehabilitation, phase I rehabilitation, exercise therapy, external counterpulsation, extracorporeal shock wave, etc.) on patients with ischemic heart disease such as coronary heart disease and heart failure, and the compliance of home rehabilitation compared with traditional cardiac rehabilitation therapy (traditional exercise rehabilitation, rehabilitation education, etc.).
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 85 years old * Female subjects no pregnancy * The main admission diagnosis of ischemic heart disease (coronary heart disease, myocardial infarction, ischemic heart failure, etc.) * The need for cardiac rehabilitation treatment Exclusion Criteria: * acute respiratory distress syndrome (ARDS); * acute episode of COPD; * uncontrolled pulmonary infection; * acute heart failure; acute pulmonary embolism; * acute myocarditis/pericarditis; * severe arrhythmia (degree II or III atrioventricular block, atrial flutter, or atrial fibrillation); * sternotomy, rib fracture, thoracic deformity, or other neurological diseases that may affect respiratory muscles
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06681506 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Ischemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06681506 currently recruiting?
Yes, NCT06681506 is actively recruiting participants. Contact the research team at liuweijing98@sina.com for enrollment information.
Where is the NCT06681506 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06681506 clinical trial?
NCT06681506 is sponsored by Shanghai 10th People's Hospital. The trial plans to enroll 100 participants.